New Data, New Opportunities, and New Clinical Challenges Using Immunotherapies for TNBC

Get up to date on the latest advances in immunotherapies for TNBC across multiple settings with expert commentaries, downloadable slides, and on-demand Webcast capturing a live CCO panel presentation.
Kevin Kalinsky, MD, MS
Heather McArthur, MD, MPH


With pembrolizumab plus chemotherapy now approved for PD-L1–positive advanced TNBC, how can we leverage this regimen for treating patients with this challenging disease? Here’s my take.

Heather McArthur, MD, MPH Released: November 20, 2020

With sacituzumab govitecan, pembrolizumab, and atezolizumab all now approved for advanced TNBC, how do we sequence these agents and how does a BRCA1/2 mutation affect sequencing decisions? Here are my thoughts.

Kevin Kalinsky, MD, MS Released: December 23, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Genentech, a member of the Roche Group
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.